142 related articles for article (PubMed ID: 33263258)
1. Chemical characterization of a PD-1/PD-L1 inhibitory activity fraction of the ethanol extract from
Lin PC; Wang X; Zhong XJ; Zhou N; Wu L; Li JJ; Hu YT; Shang XY
J Asian Nat Prod Res; 2021 Mar; 23(3):235-249. PubMed ID: 33263258
[TBL] [Abstract][Full Text] [Related]
2. Rapid Characterizaiton of Chemical Constituents of the Tubers of
Wang X; Zhong XJ; Zhou N; Cai N; Xu JH; Wang QB; Li JJ; Liu Q; Lin PC; Shang XY
Molecules; 2020 Feb; 25(4):. PubMed ID: 32085417
[No Abstract] [Full Text] [Related]
3. Study on endogenous inhibitors against PD-L1: cAMP as a potential candidate.
Huang Q; Zang X; Zhang Z; Yu H; Ding B; Li Z; Cheng S; Zhang X; Ali MRK; Qiu X; Lv Z
Int J Biol Macromol; 2023 Mar; 230():123266. PubMed ID: 36646351
[TBL] [Abstract][Full Text] [Related]
4. Glycosidic constituents of the tubers of Gymnadenia conopsea.
Zi J; Li S; Liu M; Gan M; Lin S; Song W; Zhang Y; Fan X; Yang Y; Zhang J; Shi J; Di D
J Nat Prod; 2008 May; 71(5):799-805. PubMed ID: 18348533
[TBL] [Abstract][Full Text] [Related]
5. [Study on HPLC fingerprint of Tibetan herb Gymnadenia conopsea].
Xue N; Lin PC; Xue J; Yao J; Liu RK
Zhong Yao Cai; 2013 Mar; 36(3):377-81. PubMed ID: 24010316
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of Programmed Death Receptor-1/Programmed Death Ligand-1 Interactions by Ginsenoside Metabolites.
Yim NH; Kim YS; Chung HS
Molecules; 2020 Apr; 25(9):. PubMed ID: 32365500
[TBL] [Abstract][Full Text] [Related]
7. Chemical fingerprint analysis of rhizomes of Gymnadenia conopsea by HPLC-DAD-MSn.
Cai M; Zhou Y; Gesang S; Bianba C; Ding LS
J Chromatogr B Analyt Technol Biomed Life Sci; 2006 Dec; 844(2):301-7. PubMed ID: 16934540
[TBL] [Abstract][Full Text] [Related]
8. PD-1/PD-L1 inhibitor screening of caffeoylquinic acid compounds using surface plasmon resonance spectroscopy.
Han Y; Gao Y; He T; Wang D; Guo N; Zhang X; Chen S; Wang H
Anal Biochem; 2018 Apr; 547():52-56. PubMed ID: 29428377
[TBL] [Abstract][Full Text] [Related]
9. In vitro assay for the development of small molecule inhibitors targeting PD-1/PD-L1.
Zhai W; Zhou X; Du J; Gao Y
Methods Enzymol; 2019; 629():361-381. PubMed ID: 31727249
[TBL] [Abstract][Full Text] [Related]
10. Discovery of the programmed cell death-1/programmed cell death-ligand 1 interaction inhibitors bearing an indoline scaffold.
Qin M; Cao Q; Wu X; Liu C; Zheng S; Xie H; Tian Y; Xie J; Zhao Y; Hou Y; Zhang X; Xu B; Zhang H; Wang X
Eur J Med Chem; 2020 Jan; 186():111856. PubMed ID: 31734021
[TBL] [Abstract][Full Text] [Related]
11. Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1).
Zak KM; Grudnik P; Guzik K; Zieba BJ; Musielak B; Dömling A; Dubin G; Holak TA
Oncotarget; 2016 May; 7(21):30323-35. PubMed ID: 27083005
[TBL] [Abstract][Full Text] [Related]
12. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
Xia L; Liu Y; Wang Y
Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
[TBL] [Abstract][Full Text] [Related]
13. [Immunotherapy with PD-1 and PD-L1 inhibitors for prostate cancer].
Huang L; He J
Zhonghua Nan Ke Xue; 2020 Nov; 26(10):944-948. PubMed ID: 33382229
[TBL] [Abstract][Full Text] [Related]
14. Glucosyloxybenzyl 2-Isobutylmalates from the tubers of Gymnadenia conopsea.
Morikawa T; Xie H; Matsuda H; Yoshikawa M
J Nat Prod; 2006 Jun; 69(6):881-6. PubMed ID: 16792404
[TBL] [Abstract][Full Text] [Related]
15. PD-1/PD-L1 and immunotherapy for pancreatic cancer.
Feng M; Xiong G; Cao Z; Yang G; Zheng S; Song X; You L; Zheng L; Zhang T; Zhao Y
Cancer Lett; 2017 Oct; 407():57-65. PubMed ID: 28826722
[TBL] [Abstract][Full Text] [Related]
16. Novel Small Molecule Inhibitors of Programmed Cell Death (PD)-1, and its Ligand, PD-L1 in Cancer Immunotherapy: A Review Update of Patent Literature.
Kopalli SR; Kang TB; Lee KH; Koppula S
Recent Pat Anticancer Drug Discov; 2019; 14(2):100-112. PubMed ID: 30370857
[TBL] [Abstract][Full Text] [Related]
17. [Quantitative analysis of four active constituents in Tibetan herb Gymnadenia conopsea by high-performance liquid chromatography].
Yang B; Li S; Zhang R; Wang Y; Shi J
Zhongguo Zhong Yao Za Zhi; 2009 Jul; 34(14):1819-22. PubMed ID: 19894516
[TBL] [Abstract][Full Text] [Related]
18. [Progress in research on tumor immune PD-1/PD-L1 signaling pathway in malignant bone tumors].
Huang HF; Zhu H; Yang XT; Guo XY; Li SS; Xie Q; Tian XB; Yang Z
Zhonghua Zhong Liu Za Zhi; 2019 Jun; 41(6):410-414. PubMed ID: 31216825
[TBL] [Abstract][Full Text] [Related]
19. Structure-based derivation and intramolecular cyclization of peptide inhibitors from PD-1/PD-L1 complex interface as immune checkpoint blockade for breast cancer immunotherapy.
Zhou K; Lu J; Yin X; Xu H; Li L; Ma B
Biophys Chem; 2019 Oct; 253():106213. PubMed ID: 31276987
[TBL] [Abstract][Full Text] [Related]
20. Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysis.
Duan J; Cui L; Zhao X; Bai H; Cai S; Wang G; Zhao Z; Zhao J; Chen S; Song J; Qi C; Wang Q; Huang M; Zhang Y; Huang D; Bai Y; Sun F; Lee JJ; Wang Z; Wang J
JAMA Oncol; 2020 Mar; 6(3):375-384. PubMed ID: 31876895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
